Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003264 · ClinicalTrials.gov registry record · Phase 2

Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer

A Phase 2 study of Head and Neck Cancer, sponsored by Fox Chase Cancer Center.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
12
Study locations

NCT00003264 is a Phase 2 study of Head and Neck Cancer that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 22 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (92% lower). The trial reports 12 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003264, a Phase 2 study of Head and Neck Cancer, has completed, sponsored by Fox Chase Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
12
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin plus gemcitabine in treating patients with advanced squamous cell head and neck cancer that cannot be treated by surgery or radiation therapy.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG cisplatin
  • DRUG gemcitabine hydrochloride

Study Locations (12)

Pennsylvania

  • St. Luke's Network - Bethlehem - Bethlehem
  • Delaware County Memorial Hospital - Drexel Hill
  • Harrisburg Polyclinic Medical Center - Harrisburg
  • Saint Mary Regional Center - Langhorne
  • North Penn Hospital - Lansdale
  • Paoli Memorial Hospital - Paoli
  • Fox Chase Cancer Center - Philadelphia
  • Reading Hospital and Medical Center - Reading

New Jersey

  • Hunterdon Regional Cancer Center - Flemington
  • Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County - Mount Holly
  • Riverview Medical Center - Booker Cancer Center - Red Bank
  • St. Francis Medical Center - Trenton

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 1997-10
Est. Completion 2002-06
Phase Phase 2

Sponsor

Fox Chase Cancer Center

183 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003264

The ClinicalTrials.gov registry entry for NCT00003264 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.

NCT00003264 reports 12 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New Jersey.

Frequently Asked Questions

What is clinical trial NCT00003264 about?

NCT00003264 is a clinical study titled "Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin plus gemcitabine in treating patients with advanced squamou...

What is the current status of trial NCT00003264?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 1997-10. Estimated completion is 2002-06.

What conditions does trial NCT00003264 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT00003264?

The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003264?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003264 being conducted?

This trial has 12 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.